Product
HLX14
2 clinical trials
2 indications
Indication
Healthy Male VolunteersIndication
PostmenopausalClinical trial
A Randomised, Parallel, Single-Dose, Subcutaneous Injection, Phase I Clinical Study Of HLX14 Versus Prolia® (Denosumab) In Chinese Healthy Adult Male Subjects For Comparison In Pharmacokinetic Characteristics, Safety, And ImmunogenicityStatus: Completed, Estimated PCD: 2023-09-12
Clinical trial
A Randomized, Double-Blind, International Multicentre, Parallel-Controlled Phase III Clinical Study to Evaluate Recombinant Anti-RANKL Human Monoclonal Antibody Injection (HLX14) Versus Denosumab Injection (Prolia®) in Postmenopausal Women With Osteoporosis at High Risk of FractureStatus: Active (not recruiting), Estimated PCD: 2024-04-30